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INTRODUCTION
Ever since the new 2019 coronavirus disease (COVID-19) was first identified in Wuhan, Hubei
province of China its spread has become a global pandemic affecting almost every country
worldwide. World Health Organization (WHO) has confirmed more than 71 million cases of
COVID-19 and over 1,620,000 deaths globally (until 16 December 2020) (1), and the numbers
are increasing rapidly.
There is growing evidence to suggest that people from Black (mostly African) and Asian (mostly
South Asians/South East Asians) ethnic groups are disproportionately affected by COVID-19,
leading to poorer outcomes (higher mortality and morbidity) compared to White British or
Americans (2–4). Public Health England (in August 2020) reported that Black people are 2–3 times
more likely to be infected with COVID-19 compared to White people after adjusting for age (5).
A study from 260 hospitals across England, Scotland and Wales found that people from Black and
South Asian backgrounds were, 36 and 28% respectively, more likely to be admitted for critical
care, after adjusting for age, gender and deprivation of area lived (6). Data from the intensive care
units showed that people from Black and Asian ethnic groups accounted for more than 25% of all
COVID-19 admissions (until end of July 2020) (7), despite comprising only about 11% of the total
population of the UK. COVID-19 related deaths within Black and Asian ethnic groups working in
the health care settings in the UK was even higher (63%) (8, 9).
In Chicago, USA, more than 50% of the total COVID-19 cases and nearly 70% of COVID-19
related deaths were reported in Black people, although they comprised only about 30% of Chicago’s
total population (10). Centers for Disease Control and Prevention reported that the rate of
coronavirus (COVID-19) infection was 2.6 times higher, hospitalization 4.7 times higher and deaths
2.1 times higher in Black/African Americans compared to White (Non-Hispanic) Americans (11).
In Asians, the rate of coronavirus infection reported was 1.1 times higher and hospitalization 1.3
times higher compared to White (Non-Hispanic) Americans.
Various reasons have been offered to explain why people from Black and Asian ethnic minority
groups are more at risk of coronavirus infection and mortality. These include socio-demographic
factors, underlying heath issues, overcrowded households, living in deprived areas, difficulty in
health care access due to language barriers, unhealthy lifestyles, and performing “higher-risk”
frontline healthcare or essential work (9). However, research suggests that even after adjusting
for age, gender, lifestyles, socio-economic factors, language barriers, self-reported health/disability
conditions, people from Black and Asian ethnic groups were still more likely to be infected and
die from COVID-19 than White people (12, 13). In the UK, data show that COVID-19 related
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deaths were 1.9 times higher in Black people and 1.6–1.8
times higher in Asians compared to White people, after
adjusting or age, socio-economic characteristics and self-reported
health/disability measures (13).
In exploring these health and social determinants of inequality
in ethnic minorities, differences in other factors such as low levels
of Vitamin D have not been addressed adequately. Vitamin D
deficiency poses a potential risk factor for COVID-19. Vitamin
D deficiency is identified as a risk factor in older age, diabetes,
obesity, and hypertension (14, 15) which are significantly
associated with COVID-19 (16). Recent studies showed negative
correlations betweenmean vitamin D levels and COVID-19 cases
across different European countries including Spain, Italy, and
Switzerland and in the US (17, 18). Although it is appreciated that
correlations do not suggest causality, these findings cannot be
discounted. There are number of limitations and methodological
differences in these studies. Ile et al. (17) is an ecological study
reporting only crude associations, and findings may be limited
by the fact that the number of positive cases are directly affected
by the proportion of COVID-19 tests performed, which may vary
between countries. In Kaufman et al. (18) study, vitamin D data
were obtained within the preceding 12 months and hence may
not all be up-to-date. Also, it is likely that findings from the
study may not be representative of the general population as
participants who took part belonged to certain priority groups
such as those who had symptoms, had come in contact with
people who had tested positive or who belonged to the “high-risk”
categories for COVID-19 infections.
Significant ethnic variations in the gene GC that encodes
Vitamin D binding protein (DBP) (protein that circulates
Vitamin D/metabolites in the blood) have been reported. Black
people and Asians are more likely to carry the GC1F variant of
this (GC) gene, which has been associated with low DBP levels,
and lower synthesis and metabolism of Vitamin D (19). On the
other hand, white people are more likely to carry the GC1S
variant in whom higher DBP levels are generally observed (20).
It is known that darker skin in Black people and Asians can
lead to a lower concentration of vitamin D in the blood as the
increasedmelanin in their skin reduces the absorption of sunlight
needed to produce vitamin D (21, 22). It is likely that lower
exposure to sunlight, for example, with cultural attire, may also
contribute to reduced vitamin D concentration as would more
time spent indoors during lockdown.
Serum 25-hydroxyvitamin D level of <50 nmol/L (20 ng/mL)
is classified as Vitamin D deficiency in adults (23). In Europe,
people from the dark-skinned ethnic background were found
to be more at risk of vitamin D deficiency compared to white
counterparts (22). Vitamin D deficiency has also been reported
in infants, adults and pregnant women of Asian families living in
the UK (24–26).
Vitamin D supplementation could reduce the risk of influenza
and COVID-19 infections and mortality (27) by reducing
the viral replication rates and expression of pro-inflammatory
cytokines which injure the lining of the lungs, leading to
pneumonia, thereby providing a protection against COVID-19
(28). Therefore, it is important vitamin D deficiency should not
be overlooked as an important risk factor for COVID-19 in
Black and Asian ethnic groups in whom vitamin D deficiency is
more prevalent.
It is important to acknowledge that the effect of vitamin D
deficiency on COVID-19 and its outcomes can be confounded
by obesity, that in itself poses additional risk for viral infections,
their progression and recovery. Vitamin D deficiency has been
shown to be higher in obese individuals. A systematic review and
meta-analysis, published in 2015, shows a 35% higher prevalence
of vitamin D deficiency in obese individuals (29). In addition,
obesity has been shown as an additional risk for other viral
infections such as from H1N1 and influenza A with delayed
recovery time (30, 31).
The affected immune system in COVID-19 is thought
to play an important role in obesity-induced adipose tissue
inflammation and metabolic dysfunctions such as diabetes,
hypertension, and cardiovascular disease (32). These underlying
conditions, known to be significant risk factors for COVID-19
complications, aremore prevalent in people fromAsian countries
including India, Pakistan, and Bangladesh (33). The role played
by body mass index (BMI) in COVID-19 was shown by data
from China (34), in which 88% of people who did not survive
had a higher BMI (>25 kg/m2) compared to 19% who survived,
suggesting obesity poses a significant additional risk for COVID-
19 infection and its progression.
Vitamin D has been stipulated as a risk factor in other virus
infections in people from ethnic minorities. A cross-sectional
study of vitamin D levels in 200 HIV-infected patients in south-
central US (Houston, Texas) found that nearly two-thirds (64%)
of patients were vitamin D deficient, and that African-American
(in whom HIV infection was more prevalent) were over three
times (odds ratio= 3.53)more likely to have vitaminD deficiency
compared to White Americans (35). In the UK, data from 1077
HIV patients, showed that 73.5% of patients had vitamin D
deficiency, with Black patients 3 times more likely to be deficient
(36). In Spain, a hospital-based study showed that HIV patients
from non-Caucasian background were 3.18 times more likely to
have vitamin D deficiency than fromCaucasian background (37).
Ethnic differences in vitamin D levels are also reported in
patients infected with Hepatitis B virus (HBV) and Hepatitis
C Virus (HCV). A study on African American and White
Americans infected with HCV found that vitamin D deficiency
was significantly greater in African Americans (44%) compared
to White Americans (15%) (38). A recent systematic review and
meta-analysis (39) of seven studies reported significantly reduced
vitamin D levels in patients infected with HBV than in healthy
controls, with the highest reduction in Indian patients (40).
One study by Hastie et al. (41), reported lack of evidence
on the potential link between vitamin D levels and the risk of
COVID-19 infection in people from Black and Asian ethnic
groups. The baseline data on vitamin D levels, ethnicity,
underlying health conditions, socioeconomic status, etc. of
participants enrolled in the UKBiobank (between 2006 and 2010)
were examined against those participants who tested positive for
COVID-19 in 2020. However, a number of limitations in the
study need to be taken into account. The data on Vitamin D and
health status were obtained a decade ago and these were then
examined for participants who tested positive in 2020. It is likely
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that these might have changed significantly over the course of 10
years. In addition, their analysis is based on only 32 Black people,
19 south Asians and 13 people from other ethnicities who were
hospitalized with COVID-19 over a month (between 16 March
and 17 April 2020, short time frame). We argue that this is not
representative of the general population and more research on
larger numbers is needed.
CONCLUSION
Evidence suggests vitamin D deficiency plays an important
role in the high rate of infection and mortality of COVID-
19 in Black and Asian ethnic minority groups, but more
research is needed to confirm this. This should be a priority for
future research including large clinical trials in order to better
understand the vulnerability of these ethnic groups and ascertain
the effectiveness of using vitamin D supplements to reduce the
risk of COVID-19 infection, severity and mortality. A number of
trials have led the way and examined the role of vitamin D or
its analogs/metabolites [e.g., calcitriol, calcifediol, 1,25(OH)2D3]
in preventing and treating COVID-19 (42–44). Findings suggest
that calcitriol exhibits significant potent activity against the
coronavirus infection (42), and a high dose of Calcifediol/25-
hydroxyvitamin D reduces the need for intensive care treatment
(43). Another trial showed that patients who received vitamin
D had improved clinical recovery as evidenced by shorter
lengths of hospital stay, lower oxygen requirements, and reduced
inflammatory markers (44). Whilst promising, there are a
number of limitations to these findings including small sample
sizes and selected cohorts such as people who were hospitalized.
It is also not clear whether vitamin D analogs/metabolites would
benefit people at an earlier stage of the disease. The possible role
of obesity was not considered (43) and the effects on ethnicity
has not been examined in detail on a larger sample of people
(44). While these results are encouraging, larger trials are needed
to draw firmer conclusions. Obviously, other health and social
determinants influencing the high risk of COVID-19 facing Black
people and Asians should not be overlooked.
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